Authors response to "Letter to the Editor": "Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types".
作者信息
Graf Ryon P, Gandara David R
机构信息
Foundation Medicine Inc, San Diego, California, USA
Cancer Ctr So./Div of Hem and Onc, UC Davis Department of Medicine, Sacramento, California, USA.
出版信息
J Immunother Cancer. 2025 Jul 7;13(7):e012334. doi: 10.1136/jitc-2025-012334.
Abstract
摘要
相似文献
1
Authors response to "Letter to the Editor": "Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types".
J Immunother Cancer. 2025 Jul 7;13(7):e012334. doi: 10.1136/jitc-2025-012334.
2
Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers.
Clin Cancer Res. 2025 Jul 15;31(14):2850-2863. doi: 10.1158/1078-0432.CCR-23-0824.
3
Super-high tumor mutational burden predicts complete remission following immunotherapy: from Peto's paradox to druggable cancer hallmark.
J Immunother Cancer. 2025 May 30;13(5):e010486. doi: 10.1136/jitc-2024-010486.
4
Calcium ion-binding genes can predict tumor mutation burden and immune checkpoint blockade response in a pan-cancer model.
Discov Oncol. 2025 Jul 16;16(1):1341. doi: 10.1007/s12672-025-03184-w.
5
The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Int Immunopharmacol. 2023 Nov;124(Pt B):110986. doi: 10.1016/j.intimp.2023.110986. Epub 2023 Sep 23.
6
Prognostic and immunological landscape of DDX17 in pan-cancer analysis: a comprehensive study.
Discov Oncol. 2025 Jun 17;16(1):1132. doi: 10.1007/s12672-025-02955-9.
7
Taurine-mediated metabolic immune crosstalk indicates and promotes immunosuppression with anti-PD-1 resistance in bladder cancer.
Front Immunol. 2025 Jun 24;16:1618439. doi: 10.3389/fimmu.2025.1618439. eCollection 2025.
8
The Potential of ESCO2 as a Prognostic and Immunotherapeutic Marker of Pan-Cancer and Its Role in Anti-PD-1 Treatment of Bladder Cancer.
Oncology. 2025;103(7):610-627. doi: 10.1159/000542188. Epub 2024 Nov 11.
9
CHEK2 deficiency increase the response to PD-1 inhibitors by affecting the tumor immune microenvironment.
Cancer Lett. 2024 Apr 28;588:216595. doi: 10.1016/j.canlet.2023.216595. Epub 2023 Dec 12.
10
Multi-cohort validation of a lipid metabolism and ferroptosis-associated index for prognosis and immunotherapy response prediction in hormone receptor-positive breast cancer.
Int J Biol Sci. 2025 Jun 9;21(9):3968-3992. doi: 10.7150/ijbs.113213. eCollection 2025.
本文引用的文献
1
Comment on 'Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types'.
J Immunother Cancer. 2025 Mar 28;13(3):e011943. doi: 10.1136/jitc-2025-011943.
2
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types.
J Immunother Cancer. 2025 Feb 6;13(2):e010311. doi: 10.1136/jitc-2024-010311.
3
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
Nat Cancer. 2024 Jul;5(7):1121-1129. doi: 10.1038/s43018-024-00752-x. Epub 2024 Mar 25.
4
High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.
J Immunother Cancer. 2023 Apr;11(4). doi: 10.1136/jitc-2022-006454.
5
Not all TMB assays are the same: Clinical validity of robust algorithmic germline filtering.
Cancer Cell. 2023 May 8;41(5):819-820. doi: 10.1016/j.ccell.2023.03.017. Epub 2023 Apr 13.
6
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
Cancer Cell. 2022 Oct 10;40(10):1161-1172.e5. doi: 10.1016/j.ccell.2022.08.022. Epub 2022 Sep 29.
7
Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies.
JAMA Oncol. 2022 Feb 1;8(2):287-291. doi: 10.1001/jamaoncol.2021.5153.
8
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.
Ann Oncol. 2021 Dec;32(12):1626-1636. doi: 10.1016/j.annonc.2021.09.016. Epub 2021 Oct 1.
Zotero 插件